Summary
Other Scenarios:
- VRTX - PFE
- VRTX - GSK
- PFE - PHRM
- GSK - PHRM
| Buyer: | Vertex Pharmaceuticals Incorporated (VRTX) | Last Price: | 20.57 | Market Cap.: | 2.72B |
|---|---|---|---|---|---|
| Target: | Pharmion Corporation (PHRM) | Last Price: | 69.65 | Market Cap.: | 2.59B |
Lines of Business Summary:
- Vertex Pharmaceuticals Incorporated (VRTX) competes in 1 industry and 14 product/service groups
- Pharmion Corporation (PHRM) competes in 1 industry and 7 product/service groups
- A combined entity will have 2% Product/Service Group overlap
- Vertex Pharmaceuticals Incorporated (VRTX) has 1 and Pharmion Corporation (PHRM) has 1 suppliers that rely on a material % of their business. They share 0 in common.
- Vertex Pharmaceuticals Incorporated (VRTX) has 6 and Pharmion Corporation (PHRM) has 3 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Healthcare |
|
|
926 |
Biopharmaceuticals |
|
|
377 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 14)
|
Target (Total: 5)
|
Buyern/a |
Targetn/a |
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 3)
|
Target (Total: 6)
|
Buyer (Total: 7)
|
Target (Total: 4)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 945 | 417 |
| Revenue Per Employee | 174,081.2 | 647,481.4 |
| Total Revenue | 41.0 | 67.3 |
| Total Expenses | 154.8 | 90.4 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
3.6 | 18.2 |
|
SG&A Expense
|
21.4 | 32.5 |
|
Research & Development
|
128.9 | 29.1 |
|
Other Operating Expense
|
0.0 | 0.0 |
|
Operating Income
|
-113.8 | -23.0 |
|
Unusual Income
|
0.9 | 8.0 |
|
LT Debt to Capital
|
0 | 0 |
|
Fwd P/E
|
-6.62 | -56.16 |
|
Fwd P/Rev
|
12.35 | 9.31 |
| Book Value | 332.0 | 380.0 |
|
Curr Portion of LTD/Cap Lease
|
34.2 | 0.0 |
Individual Company Summary
Focused
Buyer
Sector Pure-Play ():
Healthcare > Biopharmaceuticals
Target
Focused ():
Healthcare > Biopharmaceuticals > Oncology
Business Description
Buyer
Vertex Pharmaceuticals Incorporated (Vertex) is a biotechnology company in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. The Company is concentrating most of its drug development resources on four drug candidates: telaprevir (VX-950) for the treatment of hepatitis C virus (HCV) infection, VX-702 for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases, VX-770 for the treatment of cystic fibrosis (CF) and VX-883 for the treatment of bacterial infection. The Company also includes several drug candidates that are being developed by its collaborators. In June 2006, the Company entered into an agreement with Janssen Pharmaceutica, N.V. (Janssen), which is a Johnson & Johnson company, relating to telaprevir.
Target
Pharmion Corporation is a global pharmaceutical company that acquires, develops and commercializes products for the treatment of hematology and oncology patients. The Company has established a portfolio of approved products and product candidates focused on the hematology and oncology markets. These include Pharmion?s primary commercial products, Vidaza (azacitidine for injection), which it markets and sells as an approved treatment for myelodysplastic syndromes in the United States, Switzerland, Israel and the Philippines. and Thalidomide Pharmion 50 milligram (Thalidomide Pharmion), a therapy for the treatment of multiple myeloma and certain other forms of cancer, which it sells on a compassionate use or named patient basis in certain countries of Europe. Thalidomide Pharmion is approved in Australia, New Zealand, Turkey, Israel, South Korea and Thailand for the treatment of multiple myeloma. In January 2008, Celgene Corporation has cleared its pending acquisition of Pharmion.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
94.47 | 72.65 |
|
Operating Margin %
|
-149.82 | -40.39 |
|
Quick Ratio
|
2.89 | 4.49 |
|
Current Ratio
|
2.93 | 4.89 |
|
Coverage Ratio
|
-0.08 | -0.08 |
| Total Assets | 655.1 | 451.5 |
| Return on Equity % | -100.25 | -26.47 |
| Return on Assets % | -50.81 | -22.28 |
|
Cash+ ST Inv. Per Share
|
3.87 | 6.96 |
| Total Debt | 34.2 | 0.0 |
| Total Debt to Equity % | 10.3 | 0 |
| Total Debt to Tangible Equity % | 10.3 | 0 |
|
Debt to Asset %
|
5.22 | 0.00 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Cardiovascular System |
|
|
Vascular Disorders |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.
Target Products:
|
|
|
|
Thromboembolism |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Target Products:
|
|
|
|
Dermatology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
White Blood Cell (WBC) Disorders |
|
|
|
Myelodysplastic Syndromes (MDS) |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Therapeutics that treat and manage rmyelodysplastic syndrome by interfering with the production of DNA.
Target Products:
|
|
|
|
Immunology |
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Infectious Diseases |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Viral |
|
|
|
RNA Viruses |
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Small Cell Lung Cancer (SCLC) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the small cells in the lung by inhibiting a specific enzyme, topoisomerase II, needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Pain Management |
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of pain in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Surgery |
|
|
|
Musculoskeletal System |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.
Target Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Pfizer Inc.
|
|
n/a | 161,115.095 | 19.42 | 9.79 | 3.31 | 3.30 | n/a | |
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 129,461.592 | 12.23 | 11.87 | 2.88 | 2.82 | 12.63 | |
| Buyer | |||||||||
|
Johnson & Johnson
|
|
n/a | 181,320.483 | 17.14 | 14.04 | 2.97 | 2.79 | n/a | |
|
Pfizer Inc.
|
|
n/a | 161,115.095 | 19.42 | 9.79 | 3.31 | 3.30 | n/a | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 159,832.834 | 20.15 | 18.01 | 3.95 | 3.80 | 5.45 | |
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 129,461.592 | 12.23 | 11.87 | 2.88 | 2.82 | 12.63 | |
|
Novartis AG (ADR)
|
|
n/a | 114,196.365 | 9.56 | 14.02 | 2.93 | 2.85 | 4.08 | |
|
Abbott Laboratories
|
|
n/a | 88,930.402 | 73.92 | 17.32 | 12.31 | 3.07 | n/a | |
|
Wyeth
|
|
n/a | 54,971.695 | 12.34 | 11.25 | 2.52 | 2.39 | n/a | |
|
Amgen, Inc.
|
|
n/a | 51,480.322 | 16.26 | 11.62 | 3.49 | 3.52 | 15.61 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 47,405.122 | 22.36 | 15.93 | 2.54 | 2.34 | n/a | |
|
Gilead Sciences, Inc.
|
|
n/a | 42,750.358 | 26.47 | 23.16 | 10.11 | 8.10 | 12.36 | |
|
Schering-Plough Corporation
|
|
n/a | 33,317.681 | 17.04 | 14.34 | 2.87 | 2.61 | 2.55 | |
|
Valeant Pharmaceuticals International
|
|
n/a | 1,109.151 | 0.00 | 26.16 | 1.24 | 1.20 | n/a | |
| Target | |||||||||
|
Pfizer Inc.
|
|
n/a | 161,115.095 | 19.42 | 9.79 | 3.31 | 3.30 | n/a | |
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 129,461.592 | 12.23 | 11.87 | 2.88 | 2.82 | 12.63 | |
|
sanofi-aventis (ADR)
|
|
n/a | 108,781.945 | 18.43 | 10.63 | 2.49 | 2.72 | n/a | |
|
Genentech, Inc.
|
|
n/a | 74,569.376 | 26.92 | 22.29 | 6.36 | 5.68 | n/a | |
|
Eli Lilly & Co.
|
|
n/a | 58,598.609 | 19.84 | 13.10 | 3.14 | 2.94 | n/a | |
|
Celgene Corporation
|
|
n/a | 23,035.855 | 132.36 | 55.06 | 18.19 | 15.07 | n/a | |
|
Eisai Co., Ltd (ADR)
|
|
n/a | 11,721.708 | 16.45 | 17.41 | 1.78 | 1.70 | 2.77 | |
|
Millennium Pharmaceuticals, Inc.
|
|
n/a | 4,959.265 | 0.00 | 124.92 | 10.19 | 9.72 | 7.73 | |
|
Poniard Pharmaceuticals, Inc.
|
|
n/a | 192.697 | 0.00 | -4.97 | n/a | 5.63 | 2.23 | |
|
SuperGen, Inc.
|
|
n/a | 185.080 | 114.44 | 18.10 | 10.26 | 9.17 | 2.11 | |
|
Vion Pharmaceuticals, Inc.
|
|
n/a | 40.769 | 0.00 | -1.06 | 2,007.43 | 2,046.38 | 4.94 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
BioMed Realty Trust, Inc.
|
|
12.90% | 1,573.799 | 28.60 | 11.79 | 5.92 | 5.46 | 1.11 | |
|
Pharsight Corporation
|
|
n/a | 45.120 | 0.00 | 30.67 | 1.61 | 1.53 | 5.13 | |
|
Avalon Pharmaceuticals, Inc.
|
|
n/a | 39.161 | 0.00 | -1.65 | 26.79 | 51.08 | 1.26 | |
| Target | |||||||||
|
GPC Biotech AG (ADR)
|
|
66.00% | 127.594 | 0.00 | n/a | 4.08 | n/a | 1.69 | |
|
Celgene Corporation
|
|
n/a | 23,035.855 | 132.36 | 55.06 | 18.19 | 15.07 | n/a | |
|
salesforce.com, inc.
|
|
n/a | 6,108.132 | 531.32 | 359.71 | 9.04 | 8.03 | 16.56 | |
|
MethylGene Inc.
|
|
n/a | 91.706 | 0.00 | n/a | 6.31 | n/a | 1.84 | |
|
Ben Venue Laboratories, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Ash Stevens, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
20.00% | 129,461.592 | 12.23 | 11.87 | 2.88 | 2.82 | 12.63 | |
|
Merck & Co., Inc.
|
|
16.80% | 100,078.551 | 30.55 | 13.98 | 4.14 | 4.10 | n/a | |
|
Novartis AG (ADR)
|
|
8.10% | 114,196.365 | 9.56 | 14.02 | 2.93 | 2.85 | 4.08 | |
|
Cystic Fibrosis Foundation Therapeutics, Inc.
|
|
5.80% | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Kissei Pharmaceuticals Co., Ltd.
|
|
3.00% | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Mitsubishi Chemical Holdings Corporation
|
|
1.60% | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Johnson & Johnson
|
|
n/a | 181,320.483 | 17.14 | 14.04 | 2.97 | 2.79 | n/a | |
| Target | |||||||||
|
US Oncology, Inc.
|
|
19.00% | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Cardinal Health, Inc.
|
|
11.00% | 21,588.933 | 13.95 | 15.37 | 0.24 | 0.23 | 16.67 | |
|
McKesson Corporation
|
|
9.00% | 17,771.274 | 18.10 | 18.94 | 0.18 | 0.18 | 7.80 | |
|
Government - United Kingdom
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Johnson & Johnson
|
|
n/a | 181,320.483 | 17.14 | 14.04 | 2.97 | 2.79 | n/a | |
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 129,461.592 | 12.23 | 11.87 | 2.88 | 2.82 | 12.63 | |
|
Novartis AG (ADR)
|
|
n/a | 114,196.365 | 9.56 | 14.02 | 2.93 | 2.85 | 4.08 | |
|
Merck & Co., Inc.
|
|
n/a | 100,078.551 | 30.55 | 13.98 | 4.14 | 4.10 | n/a | |
|
Senomyx Inc.
|
|
n/a | 215.289 | 0.00 | -8.72 | 14.11 | 11.59 | 3.61 | |
|
Altus Pharmaceuticals Inc.
|
|
n/a | 157.170 | 0.00 | -2.15 | 0.00 | 20.56 | n/a | |
|
Avalon Pharmaceuticals, Inc.
|
|
n/a | 39.161 | 0.00 | -1.65 | 26.79 | 51.08 | 1.26 | |
|
Mitsubishi Chemical Holdings Corporation
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Cystic Fibrosis Foundation Therapeutics, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Kissei Pharmaceuticals Co., Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Pfizer Inc.
|
|
n/a | 161,115.095 | 19.42 | 9.79 | 3.31 | 3.30 | n/a | |
|
Celgene Corporation
|
|
n/a | 23,035.855 | 132.36 | 55.06 | 18.19 | 15.07 | n/a | |
|
Cardinal Health, Inc.
|
|
n/a | 21,588.933 | 13.95 | 15.37 | 0.24 | 0.23 | 16.67 | |
|
McKesson Corporation
|
|
n/a | 17,771.274 | 18.10 | 18.94 | 0.18 | 0.18 | 7.80 | |
|
GPC Biotech AG (ADR)
|
|
n/a | 127.594 | 0.00 | n/a | 4.08 | n/a | 1.69 | |
|
MethylGene Inc.
|
|
n/a | 91.706 | 0.00 | n/a | 6.31 | n/a | 1.84 | |
|
US Oncology, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
LEO Pharma A/S
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Ash Stevens, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Dainippon Sumitomo Pharma Co., Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Ben Venue Laboratories, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Nippon Shinyaku Co., Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 242.3 | 255.9 | 498.2 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 242.3 | 255.9 | 498.2 |
|
Cost of Revenue
|
13.4 | 70.0 | 83.4 |
|
SG&A Expense
|
77.1 | 125.2 | 202.3 |
|
Depreciation & Amortization
|
0.0 | 9.9 | 9.9 |
|
Research & Development
|
506.9 | 91.9 | 598.8 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
0.0 | 0.0 | 0.0 |
|
Unusual Expense (Income)
|
7.9 | 62.3 | 70.2 |
| Total Expenses | 605.3 | 359.2 | 964.5 |
|
Operating Income
|
-363.0 | -103.3 | -466.3 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
30.1 | 8.1 | 38.2 |
|
Other, Net
|
0.0 | 0.0 | 0.0 |
| Income Before Taxes | -332.9 | -95.3 | -428.1 |
| Income Taxes | 0.0 | 5.3 | 5.3 |
| Income After Taxes | -332.9 | -100.6 | -433.5 |
|
Net Income - Excl. Xord. Items
|
-332.9 | -100.6 | -433.5 |
|
Net Income - Incl. Xord. Items
|
-332.9 | -100.6 | -433.5 |
|
Income Avail. to Common
|
-332.9 | -100.6 | -433.5 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
130.0 | 37.0 | 167.0 |
|
Basic EPS - Excl. Xord. Items
|
n/a | n/a | -2.60 |
|
Basic EPS - Incl. Xord. Items
|
n/a | n/a | -2.60 |
| Full Dilution Adjustment | 0.0 | 0.0 | 0.0 |
| Fully Diluted Shares Outstanding | 130.0 | 37.0 | 167.0 |
|
F.D. EPS - Excl. Xord. Items
|
n/a | n/a | -2.60 |
|
F.D. EPS - Incl. Xord. Items
|
n/a | n/a | -2.60 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
254.0 | 135.0 | 389.0 |
|
ST Investments
|
248.6 | 122.6 | 371.2 |
|
Accounts Receivable
|
34.7 | 45.4 | 80.1 |
|
Inventory
|
0.0 | 13.0 | 13.0 |
|
Prepayments and Advances
|
6.1 | 0.0 | 6.1 |
|
Other Current Assets
|
0.0 | 14.0 | 14.0 |
|
Current Assets
|
543.3 | 330.0 | 873.3 |
|
Accum D&A
|
0.0 | 0.0 | 0.0 |
|
PPE, Net
|
68.9 | 11.0 | 79.9 |
| Goodwill & Intangibles | 0.0 | 104.7 | 104.7 |
| Long Term Investments | 11.9 | 0.0 | 11.9 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
31.1 | 5.8 | 36.9 |
| Total Assets | 655.1 | 451.5 | 1,106.7 |
| Liabilities | |||
| Accounts Payable | 25.8 | 10.1 | 35.8 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 101.7 | 57.5 | 159.2 |
|
ST Debt
|
0.0 | 0.0 | 0.0 |
|
Curr Port of LTD & Cap Lease Oblg
|
34.2 | 0.0 | 34.2 |
| Other (Current) Liabilities | 24.0 | 0.0 | 24.0 |
|
Current Liab.
|
185.7 | 67.5 | 253.2 |
|
LT Debt
|
0.0 | 0.0 | 0.0 |
|
Total LT Debt
|
0.0 | 0.0 | 0.0 |
| Deferred Taxes | 0.0 | 3.0 | 3.0 |
|
Other LT Liab.
|
137.4 | 1.0 | 138.4 |
|
Total Liabilities
|
323.1 | 71.5 | 394.6 |
| Shareholders Equity | |||
| Common Stock | 1.3 | 0.0 | 1.3 |
| Additional Paid in Capital | 1,832.4 | 627.5 | 2,459.9 |
| Retained Earnings | -1,502.0 | -263.2 | -1,765.2 |
| Other Equity | 0.3 | 15.7 | 16.0 |
|
Total Equity
|
332.0 | 380.0 | 712.1 |
|
Total Liab. & Equity
|
655.1 | 451.5 | 1,106.7 |
|
Shares Outstanding
|
132.2 | 37.2 | 169.3 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | -332.9 | -100.6 | -433.5 |
| CF Depreciation | 26.9 | 12.4 | 39.3 |
| CF Deferred Taxes | 0.0 | 0.0 | 0.0 |
| Other Non-Cash Items | 62.0 | 3.4 | 65.4 |
| Change in Working Capital | 39.9 | 20.2 | 60.1 |
| Total Cash From Operating Activities | -204.1 | -64.7 | -268.8 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -34.4 | -6.7 | -41.1 |
| Other Investing Cash Flows | 15.5 | -32.1 | -16.6 |
| Total Cash From Investing Activities | -18.9 | -38.8 | -57.7 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | 0.0 | 0.0 | 0.0 |
| Purchase Or Sale of Stock | 35.5 | 6.1 | 41.7 |
| Purchase and Retirement of Debt | -42.1 | -0.9 | -43.0 |
| Other Financing Cash Flow | -0.1 | 130.8 | 130.7 |
| Total Cash From Financing Activities | -6.6 | 135.9 | 129.3 |
| Exchange Rate Effects | 0.1 | 3.8 | 3.9 |
| Net Change in Cash | -229.5 | 36.2 | -193.2 |
| Cash Taxes Paid | 0.0 | 11.4 | 11.4 |
| Cash Interest Paid | 3.8 | 0.4 | 4.3 |